Foghorn Therapeutics (FHTX) stock

Gene-targeting medicines , market cap $113M

Gene-targeting medicines

Worth $113M

$1.90

-6.86%

As of Tuesday's close · Live for Pro members at the open

Why is FHTX down?

Down 6.9% today, more than its biotech peers' 1.4%; no story names it yet.

Rose on Nov 9

Up 9% on Nov 9, an up day for the market: the S&P 500 rose 2%, 84% of stocks rose, and biotech stocks a median 4%.

Its Nov 9 results: collaboration revenue was $83.5M, from $8.2M a year before. It rose 9% on Nov 9.

Sources: Price history, Nov 9, 2026; Company release, Nov 9, 2026

Tell me next time FHTX moves

Free account, no card. An optional alert when FHTX moves or its score changes.

Or see it live, free until Thursday morning. No account.

1 more reason, free with an account →3 more reasons why FHTX rose on Nov 9, from its filings, with the other side, the timeline, and its peers, for Pro members.

Why FHTX still lags the market over five years

Down 40% over the three years to Nov 9 while the S&P 500 rose 80%; up 9% on Nov 9.

3 reasons, from its filings, with the timeline, for Pro members.

Quality Score

-2

Poor

In its industry

#174of 281

Biotech

Checks firing

0of 14

Trending down

From 52-week high

-75.0%

under its best in a year

FHTX's Quality Score rose 1 point on Tue, Nov 10, to -2. A profit of $9M over the last four quarters, after a loss of $72M the four before.

Follow FHTX's trial news. Pro members can get an alert when Foghorn Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when FHTX files news on its trialSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ4 2026“Dose-range finding studies are expected to begin in the fourth quarter of 2026…”Trial start · SEC filing · Nov 9

Key facts on FHTX

Key facts on FHTX
Since its Dec 2021 high	Down 91% a $101.3M loss → $9.4M profit a year
Latest filing	8-K, Nov 9 Reported its quarterly results

1 more reason behind FHTX's -2, free with an account →5 more reasons behind FHTX's -2, for Pro members.

FHTX in the news

TodayNo story names it yet.

What's next

Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.

2 more dates ahead: conferences, for Pro members.

FHTX catalysts

Coming up

After its last 4 reports it closed 0.0% on average, higher 2 of 4 times.

What's next for FHTX, and how long its cash lasts

Next step the company has named

Q4 2026“Dose-range finding studies are expected to begin in the fourth quarter of 2026, with potential first-in-human studies by the end of 2027.”Trial start · SEC filing · Nov 9

What it means: when a trial begins, or reaches the stage the company named.

1 more trial, 2 more milestones and 45 filings, for Pro members.

Cash runway

The company says its cash lasts into the second half of 2029 (8-K, Nov 9).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Jan 24, 2025)
At-the-market share sales program (424B5, filed Mar 20, 2025)

For Pro members: 4 raises and their amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

Get an alert when Adrian Gottschalk buys or sells

For Pro members: every trade, and Adrian Gottschalk’s 14 filings and quotes.

Get an alert when FHTX files news on its trialA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why FHTX scores -2

Poorfor quality, not price, 0 of 14 chart checks firingWhat the Quality Score means

−3Long-term trend below a falling 200-⁠day average, down over one year, down over two years
+3Growth sales up 357% on the year, operating margin up 355.0 pointsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.

Size subtracts
Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
News adds

No effect today: Chart checks, Run-up, and Persistence.

What every line is worth, and the reason behind it, on FHTX and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 10:56 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How FHTX ranks in Biotech

FHTX is #174 of 281 by Quality Score.

How FHTX ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	EXELExelixis		Open for its score
	FDMT4D Molecular Therapeutics		Open for its score
	FTHFaeth Therapeutics		Open for its score
	FULCFulcrum Therapeutics		Open for its score
174	FHTXFoghorn Therapeutics	0/14	-2

When does FHTX report earnings, and what happens after?

Expected to report Thu Mar 11, before the open (in 121 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What FHTX reported on Nov 9, 2026

The quarter

A profit of $0.80 a share, from a loss of $0.25.

“The $75.4 million increase was driven by a $74.1 million cumulative catch-up adjustment primarily related to updated estimated future costs for the decision to not advance FHD-909 and the SMARCA2 selective degrader.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

FHTX's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“The $1.2 million decrease is attributed to a decrease in Lilly-partnered program costs, decreases in facilities and IT-related expenses, and decreases in personnel-related costs, partially offset by an increase in early development and other external costs.”

From its results filing (SEC filing · Nov 9)

1 more sentence, for Pro members.

The numbers

Market value: $113M; today
Sales: $112M; up 357% on the year
Free cash flow: -$83.7M; last 12 months

Its share count grew 15% a year over 3 years.

1 more figure, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on FHTX: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-10.3%+14.1%+9.1%

May 7Aug 6Nov 9

Reported	When	Gap	Reaction	5 days
Nov 9, 2026Before open	Before open	+11.2%	+9.1%	not yet
Aug 6, 2026Before open	Before open	+3.7%	+14.1%	+36.1%
May 7, 2026Before open	Before open	0.0%	-10.3%	-10.9%

FHTX closed higher after 2 of its last 4 reports.

All 4 reports, and FHTX's Quality Score going into each

FHTX sales and profit by year

Sales and profit by year

Sales grew in four of the last five years, to $30.9M in 2025. It lost money in each of the six years.

Nothing is firing on FHTX right now

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on FHTX, and all 14 on every stock.Get in free →

FHTX RSI today: 32.5, below its 50-day and 200-day averages

Not scored

RSI 32.5, MACD above signal, below both averages. Not scored.13 readings

The deep dive on FHTX

What it does and how it makes money3 findingsAn operating loss of $86.4M in fiscal 2025, on $30.9M of sales.Annual report, filed Mar 11, 2026
Where it stands3 findingsFor Pro members3 findings on where FHTX stands: its cash, debt, and share count, for Pro members
What changed in its filings1 findingA new heading in its "Risk Factors" this year: "Our use of artificial intelligence and machine learning exposes us to operational, regulatory, legal, and ethical risks that could adversely affect our business, reputation, financial condition, and results of operations." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Mar 11, 2026, against the one of Mar 6, 2025
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades FHTX, for Pro members

7 more findings on FHTX, each with its source, for Pro members.

FHTX share count over time

Shares: 13.4% more than a year ago (to Sep 30).

Shares of FHTX outstanding, as filed
Shares outstanding	As of
60M	Oct 30, 2026
59.4M	Jul 31, 2026
58.7M	Apr 30, 2026
58.7M	Feb 27, 2026

Offerings, shelves, and splits of FHTX, from its filings
From its filings	Filed
Priced a sale of shares	Jan 12, 2026
Set up an at-the-market program for up to $100M of shares, about 88% of its market value	Mar 20, 2025
Registered shares for a later sale (S-3)	Jan 24, 2025
Set up an at-the-market program for up to $190M of shares, about 168% of its market value	Aug 8, 2024

FHTX's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Adrian GottschalkChief Executive Officer · no trades on file

See insider trades by person

Which ETFs hold FHTX?

In ETFs: FHTX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Foghorn Therapeutics

Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.

106 employeesCambridge, MAfoghorntx.com

What Foghorn Therapeutics says it competes with

“The biotechnology and pharmaceutical industries are characterized by the rapid evolution of technologies and understanding of disease etiology, intense competition and a strong emphasis on intellectual property.”

From its annual report, SEC filing · Mar 11, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on FHTX and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn FHTX's score around: 7 things
8 more filings explained, a plain line each
Real-⁠time prices, no delay

See FHTX's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: FHTX's Quality Score is -2 (Poor), #174 of 281 in Biotech.

What does FHTX's Quality Score say?

FHTX scores -2 today, which Breakaway calls Poor. It is #174 of 281 in Biotech by Quality Score, with 0 of 14 chart checks firing. Up 9% on Nov 9, an up day for the market: the S&P 500 rose 2%, 84% of stocks rose, and biotech stocks a median 4%. Shares: 13.4% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is FHTX's Quality Score?

FHTX scores -2 today, which Breakaway calls Poor (below zero). That is #174 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind FHTX's -2.

When does FHTX report earnings?

Expected to report Thu Mar 11, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. FHTX closed higher after 2 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.